Sheng Su
Impact in
-
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
-
- Antibiotic Resistance in Bacteria
Papers in
-
- Circular RNAs in diseases 2
-
- Berberine and alkaloids research 1
- Inflammatory mediators and NSAID effects 1
- Co-authors
- Todd Riccobene (1 shared paper)Songyang Yu (4 shared papers)Xiaowu Huang (4 shared papers)Shao‐Lai Zhou (3 shared papers)Zhiqiang Hu (3 shared papers)Li Mao (2 shared papers)Jia Li (2 shared papers)Zheng‐Jun Zhou (2 shared papers)
- Journals
- Journal of Immunotherapy (1 paper)Antimicrobial Agents and Chemotherapy (1 paper)Cancer Science (1 paper)International Journal of Pharmaceutics (1 paper)Cancer Letters (1 paper)
- Partner nations
- ChinaEthiopiaSaudi Arabia
In The Last Decade
Sheng Su
10 papers receiving 290 citations
Peers
Comparison fields: 5 of 62
- Cancer Research 84
- Molecular Medicine 23
- Pharmaceutical Science 23
- Applied Microbiology and Biotechnology 6
- Pharmacology 50
Countries citing papers authored by Sheng Su
This map shows the geographic impact of Sheng Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheng Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheng Su more than expected).
Fields of papers citing papers by Sheng Su
This network shows the impact of papers produced by Sheng Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheng Su. The network helps show where Sheng Su may publish in the future.
Co-authors
The 25 scholars most cited alongside Sheng Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 104 | |
| 2 | 2013 | 43 | |
| 3 | Leukocytes from diabetic patients kill retinal endothelial cells: effects of berberine. | 2013 | 41 |
| 4 | 2003 | 37 | |
| 5 | 2023 | 17 | |
| 6 | 2021 | 17 | |
| 7 | 2024 | 15 | |
| 8 | 2021 | 12 | |
| 9 | 2024 | 7 | |
| 10 | 2019 | 1 | |
| 11 | 2020 | 0 |
About Sheng Su
Sheng Su is a scholar working on Molecular Biology, Pharmacology, Oncology, Pollution and Industrial and Manufacturing Engineering, having authored 11 papers that have together received 294 indexed citations. Recurring topics across this work include Recycling and Waste Management Techniques (2 papers), Ferroptosis and cancer prognosis (2 papers), Microplastics and Plastic Pollution (2 papers), Immunotherapy and Immune Responses (2 papers), Circular RNAs in diseases (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Berberine and alkaloids research (1 paper) and Inflammatory mediators and NSAID effects (1 paper). The work is most often cited by research in Cancer Research (84 citations), Molecular Medicine (23 citations), Pharmaceutical Science (23 citations), Applied Microbiology and Biotechnology (6 citations) and Pharmacology (50 citations). Sheng Su has collaborated with scholars based in China, Ethiopia and Saudi Arabia. Frequent co-authors include Todd Riccobene, Songyang Yu, Xiaowu Huang, Shao‐Lai Zhou, Zhiqiang Hu, Li Mao, Jia Li, Zheng‐Jun Zhou, Peng‐Cheng Wang and Jia Fan. Their work appears in journals such as Journal of Immunotherapy, Antimicrobial Agents and Chemotherapy, Cancer Science, International Journal of Pharmaceutics and Cancer Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.